Infinity Pharmaceuticals Inc. (INFI) Receives Consensus Recommendation of “Hold” from Brokerages

Share on StockTwits

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) has been given an average recommendation of “Hold” by the seven ratings firms that are covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $3.50.

A number of brokerages have issued reports on INFI. Zacks Investment Research raised shares of Infinity Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a research report on Thursday, March 28th. ValuEngine cut shares of Infinity Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st.

Several hedge funds have recently made changes to their positions in the company. Savant Capital LLC boosted its holdings in shares of Infinity Pharmaceuticals by 66.7% during the 4th quarter. Savant Capital LLC now owns 25,000 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 10,000 shares in the last quarter. Community Bank N.A. boosted its holdings in shares of Infinity Pharmaceuticals by 71.4% during the 1st quarter. Community Bank N.A. now owns 24,000 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 10,000 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Infinity Pharmaceuticals by 54.2% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 45,232 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 15,908 shares in the last quarter. Fosun International Ltd boosted its holdings in shares of Infinity Pharmaceuticals by 5.4% during the 4th quarter. Fosun International Ltd now owns 378,296 shares of the biotechnology company’s stock valued at $424,000 after buying an additional 19,437 shares in the last quarter. Finally, Two Sigma Investments LP boosted its holdings in shares of Infinity Pharmaceuticals by 29.4% during the 4th quarter. Two Sigma Investments LP now owns 91,296 shares of the biotechnology company’s stock valued at $108,000 after buying an additional 20,721 shares in the last quarter. Hedge funds and other institutional investors own 54.09% of the company’s stock.

Shares of Infinity Pharmaceuticals stock opened at $1.50 on Thursday. The firm has a market cap of $87.12 million, a price-to-earnings ratio of -7.50 and a beta of 2.10. Infinity Pharmaceuticals has a 12-month low of $1.00 and a 12-month high of $2.92.

Infinity Pharmaceuticals (NASDAQ:INFI) last issued its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.19). The business had revenue of $2.14 million for the quarter, compared to analyst estimates of $10.07 million. As a group, equities research analysts predict that Infinity Pharmaceuticals will post -0.55 earnings per share for the current year.

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.

Featured Article: Why is the price-sales ratio important?

Analyst Recommendations for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.